Bluejay Therapeutics Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Bluejay Therapeutics is a biotechnology research company based in San Francisco, California. Its work centers on developing therapies for infectious diseases, with chronic hepatitis D (HDV) identified as its first target indication. The organization pursues a pipeline-driven approach to address unmet needs in viral infections. In the biotechnology landscape, Bluejay positions itself as a smaller company advancing clinical programs in infectious diseases. A notable 2025 development is the enrollment of the first patient in AZURE-2, a global Phase 3 trial evaluating brelovitug (BJT-778) as monotherapy for chronic hepatitis D. This progression reflects the company’s focus on progressing HDV therapeutics through late-stage testing.